[Biotherapies and Parkinson's disease].
In the last years, several experimental biotherapies have been developed to treat Parkinson's disease. Initially, fetal dopaminergic transplants were proposed. Although a proof of concept and encouraging results have been provided, limitations of this treatment emerged over the years and the failure of controlled trials have conducted to a pause in the development of strategies based on fetal cells. Alternative approaches such as the use of retinal pigmented cells recently provided disappointing results in patients and much hope has now been reported on other sources of dopaminergic neurons such as those originating from stem cells. This strategy is however not yet ready for clinical trials in patients. Eventually, gene therapy is a new original experimental technique which has elicited several trials in the last few years some of them being promising.
Cesaro
P
P
Clinique neurologique, département de neurosciences cliniques, CHU Henri-Mondor, 51, avenue du Maréchal-De-Lattre-de-Tassigny, 94000 Créteil, France. pierre.cesaro@hmn.aphp.fr
Fenelon
G
G
Remy
P
P
D001691:Biological Therapy / Q000379:methods*; D017690:Cell Transplantation / Q000379:methods; D004298:Dopamine / Q000096:biosynthesis; D053595:Embryonic Stem Cells; D015316:Genetic Therapy; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000235:genetics; D006801:Humans; D010300:Parkinson Disease / Q000235:genetics / Q000601:surgery / Q000628:therapy*; D033581:Stem Cell Transplantation
D051100:Glial Cell Line-Derived Neurotrophic Factor; D004298:Dopamine